577 related articles for article (PubMed ID: 26371145)
21. Lobular carcinoma in situ.
Afonso N; Bouwman D
Eur J Cancer Prev; 2008 Aug; 17(4):312-6. PubMed ID: 18562954
[TBL] [Abstract][Full Text] [Related]
22. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
Wong SM; Stout NK; Punglia RS; Prakash I; Sagara Y; Golshan M
Cancer; 2017 Jul; 123(14):2609-2617. PubMed ID: 28221673
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
25. Lobular carcinoma in situ (LCIS): pathology and treatment.
Gump FE
J Cell Biochem Suppl; 1993; 17G():53-8. PubMed ID: 8007710
[TBL] [Abstract][Full Text] [Related]
26. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
[TBL] [Abstract][Full Text] [Related]
27. Lobular carcinoma in situ and invasive cancer: the contralateral breast controversy.
Carolin KA; Tekyi-Mensah S; Pass HA
Breast J; 2002; 8(5):263-8. PubMed ID: 12199752
[TBL] [Abstract][Full Text] [Related]
28. Breast conservation therapy for invasive lobular carcinoma: the impact of lobular carcinoma in situ in the surgical specimen on local recurrence and axillary node status.
Stolier AJ; Barre G; Bolton JS; Fuhrman GM; Looney S
Am Surg; 2004 Sep; 70(9):818-21. PubMed ID: 15481302
[TBL] [Abstract][Full Text] [Related]
29. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A
J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014
[TBL] [Abstract][Full Text] [Related]
30. Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS).
McEvoy MP; Coopey SB; Mazzola E; Buckley J; Belli A; Polubriaginof F; Merrill AL; Tang R; Garber JE; Smith BL; Gadd MA; Specht MC; Guidi AJ; Roche CA; Hughes KS
Ann Surg Oncol; 2015 Oct; 22(10):3346-9. PubMed ID: 26242364
[TBL] [Abstract][Full Text] [Related]
31. Lobular Carcinoma
Vora H; Kim S; Amersi F; Giuliano A; Chung A
Am Surg; 2017 Oct; 83(10):1040-1044. PubMed ID: 29391091
[TBL] [Abstract][Full Text] [Related]
32. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis.
Ben-David MA; Kleer CG; Paramagul C; Griffith KA; Pierce LJ
Cancer; 2006 Jan; 106(1):28-34. PubMed ID: 16329136
[TBL] [Abstract][Full Text] [Related]
33. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings.
Liberman L; Sama M; Susnik B; Rosen PP; LaTrenta LR; Morris EA; Abramson AF; Dershaw DD
AJR Am J Roentgenol; 1999 Aug; 173(2):291-9. PubMed ID: 10430122
[TBL] [Abstract][Full Text] [Related]
34. Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.
Mao K; Yang Y; Wu W; Liang S; Deng H; Liu J
PLoS One; 2017; 12(5):e0176417. PubMed ID: 28467490
[TBL] [Abstract][Full Text] [Related]
35. [Breast-conserving treatment for early invasive lobular breast cancer: 15 years results].
Fodor J; Sulyok Z; Polgár C; Major T; Tóth J; Németh G
Magy Seb; 2001 Aug; 54(4):209-14. PubMed ID: 11550486
[TBL] [Abstract][Full Text] [Related]
36. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience.
Hoffman DI; Zhang PJ; Tchou J
Surg Oncol; 2019 Mar; 28():190-194. PubMed ID: 30851899
[TBL] [Abstract][Full Text] [Related]
37. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
38. Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?
Beck AC; Bayard S; Plitas G; Sevilimedu V; Kuba MG; Garcia P; Morrow M; Tadros AB
Ann Surg Oncol; 2023 Oct; 30(10):6061-6069. PubMed ID: 37493892
[TBL] [Abstract][Full Text] [Related]
39. [In situ carcinomas of the breast: clinical features and therapeutic strategies].
Attene F; Scognamillo F; Trignano E; Meloni GB; Rubino C; Trignano M
Ann Ital Chir; 2006; 77(1):3-10; discussion 10-2. PubMed ID: 16910353
[TBL] [Abstract][Full Text] [Related]
40. Pattern of ipsilateral breast tumor recurrence after breast-conserving therapy.
Jobsen J; van der Palen J; Riemersma S; Heijmans H; Ong F; Struikmans H
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1006-1014. PubMed ID: 25035203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
